MP07-66

Research use only, not for human use.

MP07-66 is a novel FTY720-analog devoid of immunosuppressive effects leads to the reactivation of PP2A, which in turn triggers apoptosis of CLL cells.

MP07-66 is a novel FTY720-analog devoid of immunosuppressive effects leads to the reactivation of PP2A, which in turn triggers apoptosis of CLL cells.(In Vitro):CLL cells were incubated with increasing concentrations of MP07-66 (0-16 μM) for 24 and 48 hours and then subject to annexin V–PI flow cytometry. The level of apoptosis reached 50% and 80%, at 24 hours and 48 hours, respectively, at a MP07-66 concentration as high as 16 μM, which paralleled PARP cleavage, a marker of caspase-dependent apoptosis. In addition, the phosphorylation status of PP2A targets, namely Akt, GSK-3, and SHP-1, was negatively affected by the treatment with MP07-66, triggering known downstream events promoting apoptosis, such as Mcl-1 degradation and caspase-3 activation.

——

——

——

Metabolic Enzyme/Protease

Phosphatase

PDE7

——

——

1938056-90-6

323.47

C19H33NO3

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (772.87 mM)

CCCCCCOc1ccc(CNCC(OCC)OCC)cc1

——

(-20℃)

With Ice Pack

≥ 2 years